StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
NMRANeumora Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$0.3906▲ 3.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $72.4MShares out 1.900M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

12
  • 8.21After-hours26.08.22 08:10
    4Ownership#●●●#●●●

    Neumora Therapeutics, Inc.

    Daljit Singh Aurora, an insider at Neumora Therapeutics, reported a change in beneficial ownership of company securities on August 20, 2026. This filing serves as a standard disclosure regarding the insider's stock holdings.…more

    $0.3906+3.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.21After-hours26.08.22 08:10
    4Ownership

    Neumora Therapeutics, Inc.

    Paul L. Berns, an insider at Neumora Therapeutics, Inc., filed an SEC Form 4 on August 21, 2026, reporting a change in beneficial ownership of company securities as of August 20, 2026. This filing formalizes the adjustment in the executive's stock holdings, which investors should review.…more

    $0.3906+3.12%vs prev close
    View filingShare
  • 8.21After-hours26.08.22 08:08
    4Ownership

    Neumora Therapeutics, Inc.

    Executive Jason Duncan of Neumora Therapeutics reported an insider transaction of company shares on August 20, 2026. This filing officially notifies the SEC of changes in the executive's beneficial ownership.…more

    $0.3906+3.12%vs prev close
    View filingShare

11 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.14Pre-market26.08.14 20:00
    #●●●#●●●

    Neumora Therapeutics Appoints New CEO and Updates Pipeline Progress

    Neumora Therapeutics has appointed Dr. Joshua Pinto as CEO and confirmed that its key clinical programs remain on track. The company maintains sufficient cash reserves to fund operations into the third quarter of 2027, with multiple clinical data readouts expected later this year.…more

    $0.3906+3.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 7.27Pre-market26.07.27 20:00

    ●●●●●●●● ●●●●● ●●●●●●

    뉴모라 테라퓨틱스가 비만 치료제 후보물질 NMRA-215의 반복 독성 시험에서 긍정적인 결과를 확인하며 안전성 우려를 해소했습니다. 회사는 이번 결과를 바탕으로 2026년 4분기 임상시험계획(IND)을 제출하고 임상 1상을 시작할 예정입니다.…more

    $0.3906+3.12%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →